Medicus Pharma Ltd (MDCX)

$0.45 +0.03 (6.43%)
Market Cap 11.42M
Revenue (ttm) 0.00
Net Income (ttm) -35.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 576,400
Avg Vol 4,682,492
Day's Range N/A - N/A
Shares Out 25.55M
Stochastic %K 46%
Beta 1.16
Analysts Strong Sell
Price Target $7.00

Company Profile

Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. Medicus Pharma Ltd. has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to M...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 610 540 7515
Address:
300 Conshohocken State Road, Suite 200, Conshohocken, United States
Ulfric
Ulfric Apr. 2 at 12:06 AM
$MDCX scooped some .41 to start a swing entry ☕️
0 · Reply
juanpa9210
juanpa9210 Apr. 1 at 9:58 PM
$MDCX every single PR goes down 🙈🙈
0 · Reply
DARKP00L
DARKP00L Apr. 1 at 11:56 AM
$MDCX 07:36 on Apr. 01 2026 Medicus Pharma Issues Clarification Regarding Previously Reported Topline Results From Phase 2 Clinical Study Of SKNJCT-003 In Nodular Basal Cell Carcinoma #tradeideas
0 · Reply
JabirAlAziz
JabirAlAziz Apr. 1 at 4:51 AM
$MDCX Topline Success: In March 2026, the company reported a 73% clinical clearance rate in its highest dose cohort (200µg).
0 · Reply
thebusthebus
thebusthebus Mar. 31 at 3:17 PM
$MDCX Sign the deal already! LEO Pharma is a global leader in medical dermatology. At the 2026 J.P. Morgan Healthcare Conference, their CEO stated they are actively seeking deals for rare dermatology disease assets.
0 · Reply
thebusthebus
thebusthebus Mar. 31 at 12:22 PM
$MDCX begging to be squeezed. $GME $AMC $PLTR $HTZ
2 · Reply
Aburose
Aburose Mar. 31 at 8:20 AM
$MDCX lets go
0 · Reply
Aburose
Aburose Mar. 31 at 8:18 AM
$MDCX BRIEF-Medicus Pharma Reports Kol Validation Of Skinject Phase 2 Data Of 80% Overall Response Rate
0 · Reply
PTI127
PTI127 Mar. 31 at 1:13 AM
$ITRM $JTAI $MDCX $MOBX $EONR BIG WEEK AHEAD HERE @topstockalerts whats your favourite 🤩 here
0 · Reply
Ulfric
Ulfric Mar. 30 at 10:24 PM
$MDCX found entry for a decent bounce on confirmation of positive news. Seems like a decent dip here in the past few weeks
0 · Reply
Latest News on MDCX
Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Apr 1, 2026, 7:30 AM EDT - 4 days ago

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Mar 30, 2026, 7:30 AM EDT - 6 days ago

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Mar 26, 2026, 7:30 AM EDT - 10 days ago

Medicus Pharma Business Update Call to Highlight 80% Overall Response Rate (ORR) in Phase 2 SkinJect Study and Agentic AI-enabled Drug Development Plan

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Mar 25, 2026, 4:30 PM EDT - 10 days ago

Medicus Pharma Reports Full-Year 2025 Financial Results and Provides Corporate Update

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Mar 18, 2026, 7:30 AM EDT - 18 days ago

Medicus Pharma To Discuss Positive Skinject(R) Phase 2 Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Mar 16, 2026, 7:30 AM EDT - 20 days ago

Medicus Pharma Announces SkinJect® Phase 2 Principal Investigator and Key Opinion Leader (KOL), Babar K. Rao MD, FAAD, to Provide Clinical Interpretation of Positive Data During Business Update Webcast on March 26

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Mar 10, 2026, 7:30 AM EDT - 26 days ago

Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Mar 9, 2026, 7:30 AM EDT - 27 days ago

Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset

Medicus Pharma Stock Swings After Skin Cancer Treatment Results

Mar 5, 2026, 9:13 AM EST - 4 weeks ago

Medicus Pharma Stock Swings After Skin Cancer Treatment Results

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Mar 5, 2026, 7:30 AM EST - 4 weeks ago

Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort

Medicus Pharma To Participate in the 38th Annual Roth Conference

Mar 3, 2026, 7:30 AM EST - 4 weeks ago

Medicus Pharma To Participate in the 38th Annual Roth Conference

Medicus Pharma on Bloomberg World

Feb 12, 2026, 7:30 AM EST - 7 weeks ago

Medicus Pharma on Bloomberg World

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Feb 10, 2026, 7:30 AM EST - 7 weeks ago

Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Jan 23, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Jan 22, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Jan 20, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Jan 12, 2026, 7:30 AM EST - 2 months ago

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Jan 5, 2026, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Dec 22, 2025, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Dec 15, 2025, 7:30 AM EST - 3 months ago

Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Dec 5, 2025, 3:20 PM EST - 4 months ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Dec 1, 2025, 8:00 AM EST - 4 months ago

Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Nov 24, 2025, 8:00 AM EST - 4 months ago

Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 17, 2025, 7:30 AM EST - 4 months ago

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Nov 14, 2025, 5:00 PM EST - 5 months ago

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Nov 13, 2025, 7:30 AM EST - 5 months ago

Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Oct 29, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

Oct 22, 2025, 7:30 AM EDT - 5 months ago

Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Oct 14, 2025, 8:07 AM EDT - 6 months ago

The Vanderbilt Report: Medicus Pharma Ltd Built Three Separate Billion-Dollar Bets

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Oct 13, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Oct 7, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Sep 29, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Sep 24, 2025, 9:26 AM EDT - 6 months ago

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Sep 24, 2025, 7:30 AM EDT - 6 months ago

Medicus Pharma Ltd. To Present at Brookline Capital Markets

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Sep 18, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Sep 8, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Sep 2, 2025, 7:30 AM EDT - 7 months ago

Medicus Pharma Ltd. Completes Acquisition of Antev Limited

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Aug 21, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Aug 4, 2025, 7:30 AM EDT - 8 months ago

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Jul 23, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Jul 21, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. to Present at BTIG Virtual Biotech Conference 2025

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Jul 8, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to the Food and Drug Administration (FDA)

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Jun 30, 2025, 7:30 AM EDT - 9 months ago

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Jun 23, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Jun 12, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. to Present at 2025 Bio International Convention

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Jun 9, 2025, 7:30 AM EDT - 10 months ago

Medicus Pharma Ltd. Announces Submission of Product Development Plan to the Food and Drug Administration (FDA) to Treat External Squamous Cell Carcinoma (SCC) in Horses

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Jun 2, 2025, 1:40 PM EDT - 10 months ago

Medicus Pharma Ltd. Announces Closing of $7.0 Million Public Offering

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

May 29, 2025, 8:30 PM EDT - 11 months ago

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

May 22, 2025, 7:30 AM EDT - 11 months ago

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Ulfric
Ulfric Apr. 2 at 12:06 AM
$MDCX scooped some .41 to start a swing entry ☕️
0 · Reply
juanpa9210
juanpa9210 Apr. 1 at 9:58 PM
$MDCX every single PR goes down 🙈🙈
0 · Reply
DARKP00L
DARKP00L Apr. 1 at 11:56 AM
$MDCX 07:36 on Apr. 01 2026 Medicus Pharma Issues Clarification Regarding Previously Reported Topline Results From Phase 2 Clinical Study Of SKNJCT-003 In Nodular Basal Cell Carcinoma #tradeideas
0 · Reply
JabirAlAziz
JabirAlAziz Apr. 1 at 4:51 AM
$MDCX Topline Success: In March 2026, the company reported a 73% clinical clearance rate in its highest dose cohort (200µg).
0 · Reply
thebusthebus
thebusthebus Mar. 31 at 3:17 PM
$MDCX Sign the deal already! LEO Pharma is a global leader in medical dermatology. At the 2026 J.P. Morgan Healthcare Conference, their CEO stated they are actively seeking deals for rare dermatology disease assets.
0 · Reply
thebusthebus
thebusthebus Mar. 31 at 12:22 PM
$MDCX begging to be squeezed. $GME $AMC $PLTR $HTZ
2 · Reply
Aburose
Aburose Mar. 31 at 8:20 AM
$MDCX lets go
0 · Reply
Aburose
Aburose Mar. 31 at 8:18 AM
$MDCX BRIEF-Medicus Pharma Reports Kol Validation Of Skinject Phase 2 Data Of 80% Overall Response Rate
0 · Reply
PTI127
PTI127 Mar. 31 at 1:13 AM
$ITRM $JTAI $MDCX $MOBX $EONR BIG WEEK AHEAD HERE @topstockalerts whats your favourite 🤩 here
0 · Reply
Ulfric
Ulfric Mar. 30 at 10:24 PM
$MDCX found entry for a decent bounce on confirmation of positive news. Seems like a decent dip here in the past few weeks
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 30 at 1:57 PM
$MDCX Great news!
2 · Reply
woodruffn2
woodruffn2 Mar. 30 at 12:41 PM
$MDCX someone will swoop in and buy this company. Big pharma will lose lots of money when this gets approved the stock is crap now but it has massive upside
1 · Reply
GABBYGIRL
GABBYGIRL Mar. 30 at 11:49 AM
$MDCX New PR out!https://dilution.news/915c22a6a4fcd642366eaeb152c2ddc7
0 · Reply
DARKP00L
DARKP00L Mar. 30 at 11:33 AM
$MDCX 07:32 on Mar. 30 2026 Medicus Pharma Reports ~80% Overall Response Rate, 73% Clinical Clearance From Clinical Validation Of Phase 2 SkinJect Dataset #tradeideas
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Mar. 27 at 7:02 PM
$MDCX Will this crash to $50K ish?
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Mar. 27 at 2:05 PM
$MDCX What a great progress!!!! Just about 72% down!!! What kind of MORONS running this POS???? I am wondering when will this garbage be delisted??
0 · Reply
biotrade123
biotrade123 Mar. 26 at 5:19 PM
$MDCX this pos is done.
0 · Reply
showmethemoney75
showmethemoney75 Mar. 26 at 4:04 PM
$MDCX These guys are burning through cash. Only have 8.7 million cash equivalents . That won’t keep the lights on for long…. Still a long ways off from going to market with anything correct?
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 26 at 4:02 PM
$MDCX all good to go. Should hit scanners soon enough.
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 26 at 3:58 PM
$MDCX volume is picking up now....hang on, we are going higher
1 · Reply
GABBYGIRL
GABBYGIRL Mar. 26 at 3:52 PM
$MDCX The call today was all positive. Mkts will find this very soon, only up from here, great products developed & awesome success so far with skin jet.
0 · Reply
GABBYGIRL
GABBYGIRL Mar. 26 at 3:45 PM
$MDCX this mkt is insane fabulous product with awesome success.
1 · Reply